C43 Stock Overview
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF67.50 |
52 Week High | CHF70.50 |
52 Week Low | CHF35.00 |
Beta | 1.2 |
1 Month Change | 0% |
3 Month Change | 25.00% |
1 Year Change | 20.54% |
3 Year Change | -8.78% |
5 Year Change | -13.79% |
Change since IPO | 400.00% |
Recent News & Updates
Recent updates
Shareholder Returns
C43 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | 3.0% | 1.3% |
1Y | 20.5% | -25.6% | 6.4% |
Return vs Industry: C43 exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.
Return vs Market: C43 exceeded the German Market which returned 6.4% over the past year.
Price Volatility
C43 volatility | |
---|---|
C43 Average Weekly Movement | 3.9% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C43 has not had significant price volatility in the past 3 months.
Volatility Over Time: C43's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 319 | Alessandro Della Cha | https://www.cosmopharma.com |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers’ diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
C43 fundamental statistics | |
---|---|
Market cap | €1.10b |
Earnings (TTM) | €1.15m |
Revenue (TTM) | €96.72m |
956.4x
P/E Ratio11.3x
P/S RatioIs C43 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
C43 income statement (TTM) | |
---|---|
Revenue | €96.72m |
Cost of Revenue | €39.34m |
Gross Profit | €57.38m |
Other Expenses | €56.24m |
Earnings | €1.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 0.071 |
Gross Margin | 59.33% |
Net Profit Margin | 1.19% |
Debt/Equity Ratio | 0.1% |
How did C43 perform over the long term?
See historical performance and comparison